Sugi Predict

Sugi Predict / Compounds / SCHEMBL63074

SCHEMBL63074

SCHEMBL63074

OB(O)c1n[nH]c2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.52
▸ GAA P10253 2/20 0.52
▸ PDPK1 O15530 1/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ IDO1 P14902 4/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ ALPL P05186 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ TTK P33981 1/20 0.48
▸ MAPK10 P53779 1/20 0.48
▸ MAP2K4 P45985 2/20 0.46
▸ CYP1A2 P05177 1/20 0.44
▸ CTNNB1 P35222 1/20 0.44
▸ WNT3A P56704 1/20 0.44
▸ YTHDC1 Q96MU7 1/20 0.43
▸ STAT3 P40763 1/20 0.43
▸ HIF1A Q16665 1/20 0.43
▸ FADS1 O60427 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ MAPKAPK3 Q16644 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954805 1.00 KDM4E (0.52) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL1101791 0.83 KDM4E (0.56) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL27158631 0.73 MAP2K4 (0.53) KDM4EGAAALDH1A1HPGDMAP2K4
SCHEMBL476840 0.72 KDM4E (0.39) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL276725 0.71 KDM4E (0.58) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL25346553 0.71 KMT2A (0.39) KDM4ELRRK2CDK2AURKA
SCHEMBL27728321 0.71 RARG (0.50) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL1672674 0.70 IDO1 (0.78) KDM4EGAAPDPK1CYP3A4IDO1
Hydrochloric Acid SCHEMBL28343698 0.70 KDM4E (0.56) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL29481432 0.69 PDPK1 (1.00) KDM4EGAAPDPK1CYP3A4IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107076-A1 CDK2 INHIBITOR COMPOUNDS ALEKSIA THERAPEUTICS, INC. (US) 2026-05-21 — — WO disclosed
EP-4713096-A1 CDK INHIBITOR COMPOUNDS Aleksia Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
EP-4688788-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS Pfizer Inc. (US) 2026-02-11 — — EP disclosed
US-12281127-B2 Pyrido[4,3-d]pyrimidine compounds PFIZER INC. (US) 2025-04-22 — — US disclosed
US-20250034173-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS PFIZER INC. (US) 2025-01-30 — — US disclosed
WO-2024238574-A1 CDK INHIBITOR COMPOUNDS ALEKSIA THERAPEUTICS, INC. (US) 2024-11-21 — — WO disclosed
WO-2024209339-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS PFIZER INC. (US) 2024-10-10 — — WO disclosed
US-20240336631-A1 Pyrido[4,3-d]pyrimidine Compounds PFIZER INC. (US) 2024-10-10 — — US disclosed
US-20240228523-A1 Metal complexes UDC IRELAND LTD (IE) 2024-07-11 — — US disclosed
US-20240228523-A1 Metal complexes UDC IRELAND LTD (IE) 2024-07-11 — — US disclosed
US-7282588-B2 Azaindole inhibitors of aurora kinases SMITHKLINE BEECHAM (US) 2007-10-16 — — US disclosed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 — — WO disclosed
WO-2007076348-A2 AZAINDOLE INHIBITORS OF AURORA KINASES SMITHKLINE BEECHAM CORPORATION (US) 2007-07-05 — — WO disclosed
US-20070149561-A1 AZAINDOLE INHIBITORS OF AURORA KINASES GLAXOSMITHKLINE LLC 2007-06-28 — — US disclosed
EP-1745033-A2 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES NEUROGEN CORPORATION (US) 2007-01-24 — — EP disclosed
US-20050277654-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2005-12-15 — — US disclosed
WO-2005110416-A2 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES NEUROGEN CORPORATION (US) 2005-11-24 — — WO disclosed
EP-1565452-A2 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS NEUROGEN CORPORATION (US) 2005-08-24 — — EP disclosed
US-20040158067-A1 3-substituted-6-aryl pyridines NEUROGEN CORPORATION 2004-08-12 — — US disclosed
WO-2004043925-A2 3-SUBSTITUTED-6-ARYL PYRIDINED AS LIGANDS OF C5A RECEPTORS NEUROGEN CORPORATION (US) 2004-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277654-A1 4,5-Disubstituted-2-aryl pyrimidines C5AR2, C3AR1, C5AR1 KDM4E 2238/4885GAA 4831/4885PDPK1 2956/4885
US-20070149561-A1 AZAINDOLE INHIBITORS OF AURORA KINASES AURKA, AURKC, AURKB KDM4E 317/4885GAA 2278/4885PDPK1 318/4885
US-20240228523-A1 Metal complexes MCU, IMMT, SOD1 KDM4E 4540/4885GAA 2702/4885PDPK1 4348/4885
US-20240336631-A1 Pyrido[4,3-d]pyrimidine Compounds DPYD, PNPO, TYMP KDM4E 2089/4885GAA 1980/4885PDPK1 405/4885
US-12281127-B2 Pyrido[4,3-d]pyrimidine compounds DPYD, PNPO, TYMP KDM4E 2089/4885GAA 1980/4885PDPK1 405/4885
US-20250034173-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS DPYD, PNPO, TYMP KDM4E 2089/4885GAA 1980/4885PDPK1 405/4885
US-20040158067-A1 3-substituted-6-aryl pyridines C3AR1, C5AR1, C5AR2 KDM4E 2711/4885GAA 4839/4885PDPK1 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.